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lucose for the Heart
oo Much of a Good Thing?*
einrich Taegtmeyer, MD, DPHIL, FACC
ouston, Texas
eart disease, often presenting as premature and accelerated
oronary artery disease, is a frequent complication of diabe-
es mellitus (1,2). The systemic metabolic dysregulation,
anifested as hyperglycemia and hypertriglyceridemia with
ncreased plasma fatty acid levels, affects both the vascula-
ure and the myocardium and, ultimately, metabolic dys-
egulation results in contractile dysfunction of the heart (3).
here is strong evidence for a close association between
ostprandial hyperglycemia and the development of cardio-
ascular diseases (4), and practitioners of cardiovascular
edicine are well aware of the importance of strict glycemic
ontrol to forestall early morbidity and mortality of patients
ith diabetes from cardiovascular disease. Intensive blood
lucose control substantially decreases the risk of microvas-
ular complications in patients with type 2 diabetes (5).
urthermore, an independent line of evidence suggests that
mpaired coronary flow reserve is an early indicator of
dverse outcomes of coronary heart disease (6). Insulin
ncreases coronary flow in the normal heart (7), most likely
y nitric oxide-induced vasodilatation (8,9). It seems, there-
ore, reasonable to argue that insulin deficiency assumes a
ausative role for the development of an impaired coronary
ow reserve in the heart of patients with type 1 diabetes
ellitus and that this impaired coronary flow reserve may
lso trigger early metabolic (10) and structural remodeling
f the myocardium (11,12). The hypothesis is strengthened
y reduced (endothelium-dependent and endothelium-
ndependent) coronary vasodilator function in type 1 and 2
iabetes (13) and in obesity associated with insulin resis-
ance (14).
See page 42
The study of Srinivasan et al. (15) in this issue of the
ournal presents evidence in support of the hypothesis that
yperglycemia negates any salutary effects of hyperinsulin-
mia on coronary vasodilatory function in patients with type
diabetes mellitus and is in line with the notion that
xposure to high concentrations of glucose has consistently
een demonstrated to impair endothelium-dependent nitric
xide-mediated vasodilatation (16) by inhibiting endothelial
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Internal Medicine, Division of Cardiology, The Univer-s
ity of Texas Houston Medical School, Houston, Texas. Dr. Taegtmeyer received
rant support from the National Heart, Lung, and Blood Institute.itric oxide synthase (17). The authors used adenosine, a
ell-known coronary vasodilator, to assess coronary flow
eserve and radiolabeled water to measure coronary flow by
ositron emission tomography. This model is a well-
stablished one in the measurement of myocardial blood
ow at rest (MBFr) and during adenosine infusion (MBFa)
nd to express the myocardial perfusion reserve (MBFa/
BFr).The results suggest that hyperglycemia has delete-
ious effects on myocardial perfusion reserve and that these
ffects outweigh any beneficial effects of hyperinsulinemia.
Given the central role of glucose as the main fuel for
nergy production in the fetal, stressed, hypertrophied, and
schemic heart muscle (18), it seems paradoxical that there
hould ever be too much of a good thing. Nature probably
oes not work that way. Yet there is vast array of literature
n glucotoxicity (19), including increased flux through the
exosamine biosynthetic pathway, superoxide production,
dvanced glycation end-products, and modification of pro-
ein function by glycosylation. The well-known marker of
rotein glycation and of glycemic control, hemoglobin Alc,
s just the proverbial tip of an iceberg. There is also the
amous study from Belgium showing that tight glycemic
ontrol improves the survival of patients in intensive care
20). However, is glycemic control really the key? This
ituation is probably more complex.
Before the results of the present study can be accepted,
he critical reader is likely to raise a number of points. First,
he data show (not unexpectedly) that adenosine profoundly
ncreases myocardial blood flow without changing the rate
ressure product of the heart. Normally, there is tight
oupling between myocardial blood flow, myocardial oxygen
onsumption (MVO2), and cardiac work (21,22). Data on
VO2 would have helped to answer the question of whether
he increase in coronary flow was associated with a decrease
n efficiency (i.e., a decrease in the amount of useful
ontractile work for the amount of energy delivered). Data
n MVO2 also would have helped to validate the model.
econd, there are no controls of age-matched patients
ithout diabetes. Data on coronary perfusion reserve of
ontrol subjects with the hyperglycemic hyperinsulinemic
lamp protocol would have provided information whether
he observed phenomenon is specific for patients with
iabetes.
Third, and probably most importantly, the exact infusion
ates of insulin in the clamp studies must be known. The
esults presented in Figure 2 of the paper by Srinivasan et al.
15) show somewhat-lower plasma insulin levels in the
yperglycemic hyperinsulinemic group receiving adenosine
han plasma insulin levels in the hyperinsulinemic euglyce-
ic group. This result, taken together with a higher resting
yocardial blood flow in the hyperglycemic hyperinsulin-
mic group (Fig. 3 of the paper by Srinivasan et al. [15]),
ay have resulted in a low value for the myocardial
erfusion reserve. Nonetheless, the multivariable analysis
uggested that glucose levels were more important than
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Editorial Comment July 5, 2005:49–50nsulin levels with respect to myocardial perfusion reserve.
he aforementioned arguments seem complicated; how-
ver, it is worthwhile to retrace the steps before we com-
letely abandon an effective treatment for many forms of
eart failure and myocardial ischemia. This is the time-
onored infusion of glucose, insulin, and potassium, also
ffective in diabetic patients with acute myocardial infarc-
ion (23–25).
That said, Srinivasan et al. (15) have exposed an impor-
ant and largely overlooked phenomenon in need of further
lucidation. To paraphrase Albert Einstein, “Nature tends
o hold on to her secrets, but nature is not wicked.” The
etabolic dysregulation that underlies the clinical manifes-
ation of type 1 diabetes includes an oversupply of fuel for
he heart. The heart fails in the midst of plenty, a phenom-
non we described as “glucolipotoxicity” (3,26). In the
etting of this study, impaired myocardial perfusion reserve
ould actually reduce the delivery of substrate to the
yocardium. The question is then, could this be a protective
henomenon?
cknowledgment
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